

Vasostrict - (20 units/mL; Solution, Intravenous)

Generic Name	Vasopressin	Innovator	Par Pharma
Dosage	20 units/mL; Solution, Intravenous	Branded US Sales	Less Than \$1000 mn
Probable FTF	Less Than 5	Known Para IV Filers	More Than 5
Other ANDA developers	More Than 5	Tentative Approvals	None
Final Approvals	More Than 5	Generic Launches	More Than 5
Indication	Indicated to increase blood pressure in adults with vasodilatory shock (e.g., postcardiotomy or sepsis) who remain hypotensive despite fluids and catecholamines.		
Complexities	Yes		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact $\underline{contact@researchdelta.com}$ to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact $\underline{contact@researchdelta.com}$ to get Detailed Information.

Chronology Of Events



Vasostrict - (40 units/100 mL and 60 units/100 mL; Solution, Intravenous)

Generic Name	Vasopressin	Innovator	Par sterile products
Dosage	40 units/100 mL and 60 units/100 mL ; Solution, Intravenous	Branded US Sales	Less Than \$1000 mn
Probable FTF	Less Than 5	Known Para IV Filers	Less Than 5
Other ANDA developers	Less Than 5	Tentative Approvals	None
Final Approvals	None	Generic Launches	None
Indication	None		
Complexities	No		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact $\underline{contact@researchdelta.com}$ to get Detailed Information.

Chronology Of Events



Vasostrict - (20 units/100 mL; Solution, Intravenous)

Generic Name	Vasopressin	Innovator	Par sterile products
Dosage	20 units/100 mL; Solution, Intravenous	Branded US Sales	Less Than \$1000 mn
Probable FTF	Less Than 5	Known Para IV Filers	Less Than 5
Other ANDA developers	More Than 5	Tentative Approvals	None
Final Approvals	Less Than 5	Generic Launches	None
Indication	Vasostrict is indicated to increase blood pressure in adults with vasodilatory shock (e.g., post-cardiotomy or sepsis) who remain hypotensive despite fluids and catecholamines		
Complexities	Yes		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact $\underline{contact@researchdelta.com} \ to \ get \ Detailed \ Information.$

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events



Vasostrict - (200 units/10 mL; Solution, Intravenous)

Generic Name	Vasopressin	Innovator	Par Pharma
Dosage	200 units/10 mL; Solution, Intravenous	Branded US Sales	Less Than \$1000 mn
Probable FTF	Less Than 5	Known Para IV Filers	Less Than 5
Other ANDA developers	More Than 5	Tentative Approvals	Less Than 5
Final Approvals	None	Generic Launches	None
Indication	Indicated to increase blood pressure in adults with vasodilatory shock (e.g., postcardiotomy or sepsis) who remain hypotensive despite fluids and catecholamines.		
Complexities	Yes		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact $\underline{contact@researchdelta.com}$ to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events